Bravo for Roche's multiple sclerosis drug in Phase III OPERA studies
This article was originally published in Scrip
Executive Summary
Hopes for Roche's novel multiple sclerosis treatment, ocrelizumab, are rising after it outperformed Rebif (interferon beta-1a) in two Phase III trials in the most common relapsing-remitting form of the disease.